Biosimilars have also made inroads among generic suppliers. But development is lengthy and expensive. McKinsey estimates that ...

In November, Amneal received FDA approval for exenatide, its first generic injectable glucagon-like peptide-1 (GLP-1) agonist ...

Researchers conducted a systematic review and meta-analysis of nine randomized controlled trials assessing exenatide (Byetta, AstraZeneca), liraglutide (Victoza/Saxenda, Novo Nordisk), semaglutide ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

One recent analysis found that, over the course of three years, people taking semaglutide (the compound in Ozempic and the ...

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Data Sources: PubMed was searched (to December 5, 2011) using the terms exenatide, liraglutide, albiglutide, and lixisenatide. The search was limited to studies published in English and conducted ...

Neither albiglutide nor exenatide therapy resulted in significant ... and head-to-head versus glargine and liraglutide. One study will also evaluate albiglutide versus sitagliptin in patients ...

Research has found that an older and less common drug, exenatide (sold under the brand ... including semaglutide and liraglutide, are more mixed. Some experts think that the molecules in those ...

Liraglutide is marketed by Novo Nordisk in three formulations ... is priced between R2 700 and R3 300. Exenatide was the first GLP-1 agonist brought to market for the treatment of diabetes. It was ...

Meanwhile, the start of phase III trials of oral semaglutide is also a boost for Novo after it published disappointing results from a trial of Victoza in type 1 diabetes this week, revealing that ...